Schering Seeks Salvation In External Deals; Hassan Outlines Licensing Plan
Executive Summary
The solution to the "innovation threat" facing big pharma lies in making deals outside the company, Schering-Plough CEO Fred Hassan said during an R&D update Nov. 1
You may also be interested in...
Schering Gets CNS As Second Therapeutic “Corner” Via Organon Acquisition
Schering-Plough's planned acquisition of Organon would provide Schering with the entrée into the central nervous system marketplace it has been seeking
Schering Gets CNS As Second Therapeutic “Corner” Via Organon Acquisition
Schering-Plough's planned acquisition of Organon would provide Schering with the entrée into the central nervous system marketplace it has been seeking
Schering-Plough To Hone Its Edge In “Build The Base” Phase
Schering-Plough is in a strong financial position for deal-making as it moves into the "build the base" phase of its restructuring initiative, where the firm is actively looking for acquisitions to bolster its R&D portfolio, CEO Fred Hassan said during the company's third quarter earnings call Oct. 20